<DOC>
	<DOCNO>NCT02305615</DOCNO>
	<brief_summary>This prospective , multi-center , observational study investigate effectiveness safety Avastin ( bevacizumab ) routine clinical practice patient metastatic colorectal cancer . Patients initiated first-line treatment fluoropyrimidine-based doublet chemotherapy plus Avastin accord Avastin Summary Product Characteristics ( SmPC ) . Target patient enrollment 300 Hungary .</brief_summary>
	<brief_title>An Observational Study Continued Avastin Plus Chemotherapy Until First Progression Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Age &gt; /= 18 year Patients histologically confirm colorectal cancer metastatic lesion Patients initiated firstline treatment fluoropyrimidinebased doublet chemotherapy plus bevacizumab accord Avastin SmPC Patients previously receive minimum 9 cycle 5fluorouracil ( 5FU ) base minimum 6 cycle capecitabinebased induction doublet chemotherapy ( i.e . 5FU capecitabine + oxaliplatin irinotecan ) plus bevacizumab Disease evaluation show stable disease , progressive disease complete response accord Response Evaluation Criteria Solid Tumors ( RECIST ) within one month Able willing provide write informed consent comply study protocol Contraindication receive Avastin accord Avastin SmPC Patients receive 10 cycle 5FUbased 7 cycle capecitabinebased induction doublet chemotherapy plus bevacizumab Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>